Clinical Trials Sponsored by Janssen Infectious Diseases BVBA

Total 33 results

Janssen Infectious Diseases BVBA

Completed

Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis

Hepatitis C Virus Infection

United States, Canada
Janssen Infectious Diseases BVBA

Withdrawn

A Study to Evaluate the Efficacy and Safety of TMC207 in Patients With Pulmonary Infection With Multi-drug Resistant Mycobacterium Tuberculosis

Multi-drug Resistant Tuberculosis

China, Ukraine, Taiwan, Korea, Republic of, Peru, Brazil, Estonia, Latvia, Philippines, Russian Federation, South Africa, Thailand, Turkey, Georgia, Mexico, Cambodia, Ethiopia
Janssen Infectious Diseases BVBA

Completed

A Study to Assess Safety and Pharmacokinetics of Telaprevir in Patients With Hepatic Impairment

Hepatic Impairment

Germany, Czech Republic
Janssen Infectious Diseases BVBA

Completed

A Study to Evaluate the Pharmacokinetic Effects of Different Storage Conditions for a Long-Acting Nanosuspension of Rilpivirine on Pharmacokinetics

Human Immunodeficiency Virus Type 1

Belgium
Janssen Infectious Diseases BVBA

Approved for marketing

Early Access of TMC207 in Patients With Extensively Drug Resistant or Pre-XDR Pulmonary Tuberculosis

Tuberculosis

Russian Federation, Lithuania
Janssen Infectious Diseases BVBA

Completed

Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis

Hepatitis C Virus Infection

United States, Canada
Janssen Infectious Diseases BVBA

Completed

A Study to Assess the Relative Bioavailability of TMC207 Following Single-Dose Administrations of Two Pediatric Formulations in Healthy Adult Participants

Healthy | Biological Availability

Netherlands
Janssen Infectious Diseases BVBA

Completed

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-63623872 in Healthy Japanese Adult Participants

Healthy

United Kingdom
Janssen Infectious Diseases BVBA

Completed

To Evaluate the Safety, Tolerability, and Efficacy of TMC207 as Part of an Individualized Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Participants With Sputum Smear-positive Pulmonary MDR-TB.

Tuberculosis

China, Ukraine, Korea, Republic of, Peru, Estonia, Kenya, Latvia, Philippines, Russian Federation, South Africa, Thailand, Turkey
Janssen Infectious Diseases BVBA

Completed

A Study to Assess the Drug-Drug Interaction Between VX-787 and Oseltamivir

Healthy

Belgium
Janssen Infectious Diseases BVBA

Completed

TMC207-TiDP13-C208: Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Participants With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB).

Tuberculosis

South Africa, Peru, Latvia, Philippines, Russian Federation, Thailand, Brazil, India
Janssen Infectious Diseases BVBA

Completed

A Study to Investigate the Potential Pharmacokinetic Interactions Between Phenytoin or Carbamazepine and Telaprevir

Healthy Participants

Netherlands
Janssen Infectious Diseases BVBA
Vertex Pharmaceuticals Incorporated

Completed

VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection

Genotype 1 Chronic Hepatitis C | Treatment Naive

United States, Australia, France, Poland, United Kingdom, Belgium, Germany, Spain, Sweden, Brazil, Austria, Ireland, Mexico
Janssen Infectious Diseases BVBA
Vertex Pharmaceuticals Incorporated

Completed

VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo

Hepatitis C, Chronic

United States, Australia, United Kingdom, Germany, France, Spain, Belgium, Netherlands, Canada, Brazil, Puerto Rico, Poland, Sweden, Switzerland, Israel
ANRS, Emerging Infectious Diseases
Janssen Pharmaceuticals

Completed

Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa (MOBIDIP)

HIV Infection

Cameroon, Burkina Faso, Senegal
ANRS, Emerging Infectious Diseases
Janssen-Cilag Ltd.

Completed

Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen (TelapreVIH)

HIV Infection | Hepatitis C, Chronic

France
ANRS, Emerging Infectious Diseases
Janssen-Cilag Ltd.

Terminated

Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR)

Viremia | HIV-1 Infection | Treatment Resistant Disorders

France
ANRS, Emerging Infectious Diseases
Gilead Sciences; Janssen Pharmaceutica

Completed

Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé) (2LADY)

HIV Infections | HIV

Burkina Faso, Cameroon, Senegal
National Institute of Allergy and Infectious Diseases...
Janssen Pharmaceuticals

Completed

A Study of Itraconazole in the Treatment and Prevention of Histoplasmosis, a Fungal Infection, in Patients With AIDS

HIV Infections | Histoplasmosis

United States
National Institute of Allergy and Infectious Diseases...
Janssen Pharmaceuticals

Completed

A Study of Letrazuril in the Treatment of AIDS-Related Diarrhea

HIV Infections | Cryptosporidiosis

United States
ANRS, Emerging Infectious Diseases
Merck Sharp & Dohme LLC; Janssen-Cilag Ltd.

Completed

Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL

HIV-1 Infection

Spain, France
Janssen Vaccines & Prevention B.V.
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

A Study to Evaluate Safety, Tolerability, and Immunogenicity of Heterologous Prime-boost Regimens Using the Multivalent Filovirus Vaccines Ad26.Filo and MVA-BN-Filo Administered in Different Sequences and Schedules in Healthy Adults

Healthy

United States
ANRS, Emerging Infectious Diseases
Merck Sharp & Dohme LLC; Pfizer; Gilead Sciences; Janssen-Cilag Ltd.

Completed

Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)

HIV-1 Infections

France
National Institute of Allergy and Infectious Diseases...
National Institutes of Health (NIH); Janssen, LP

Recruiting

An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge

Dengue

United States
ANRS, Emerging Infectious Diseases
Bristol-Myers Squibb; Merck Sharp & Dohme LLC; Gilead Sciences; Roche Pharma AG; Janssen-Cilag...

Active, not recruiting

Therapeutic Option for Hepatitis B and C: a French Cohort (HEPATHER)

Viral Hepatitis C | Viral Hepatitis B

France
Kirby Institute
National Institute of Allergy and Infectious Diseases (NIAID); ViiV Healthcare and other collaborators

Withdrawn

Inflammation and Co-Infections in D²EFT (i2-D²EFT)

Cytomegalovirus Infections | Human Papilloma Virus | HIV-infection/Aids | Human Herpesvirus 4 Infections | Human Herpesvirus 8 Infection
Kirby Institute
National Health and Medical Research Council, Australia; National Institute... and other collaborators

Active, not recruiting

Dolutegravir and Darunavir Evaluation in Adults Failing Therapy (D²EFT)

HIV Infections

Mexico, Thailand, Malaysia, Argentina, Brazil, India, Nigeria, South Africa, Chile, Colombia, Guinea, Indonesia, Mali, Zimbabwe
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID); Merck Sharp... and other collaborators

Completed

A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure (MULTI-OCTAVE)

HIV-1 Infection

Kenya, Brazil, South Africa, Uganda, Zimbabwe, India, Malawi, Haiti, Thailand, Peru
Janssen Vaccines & Prevention B.V.
National Institute of Allergy and Infectious Diseases (NIAID); Beth Israel... and other collaborators

Completed

Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention

Healthy

United States, South Africa, Thailand, Uganda, Rwanda
University of Washington
National Institute of Allergy and Infectious Diseases (NIAID); Merck Sharp... and other collaborators

Terminated

RESIST-2: 2nd-line ART for HIV-2 Infection (RESIST-2)

HIV-2 Infection

Senegal
Boris Juelg, MD PhD
National Institute of Allergy and Infectious Diseases (NIAID); The University... and other collaborators

Recruiting

Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults

Acquired Immunodeficiency Syndrome | Sexually Transmitted Diseases, Viral | Retroviridae Infections | HIV | Immunologic Deficiency Syndrome, Acquired

United States
U.S. Army Medical Research and Development Command
National Institute of Allergy and Infectious Diseases (NIAID); Duke University and other collaborators

Not yet recruiting

Evaluation of Safety and Immunogenicity of Ad26.Mos4.HIV and CH505 TF chTrimer Combination in Healthy Adults (RV591)

Human Immunodeficiency Virus

Uganda
Wits Health Consortium (Pty) Ltd
Fred Hutchinson Cancer Center; Janssen Vaccines & Prevention B.V.; Right to Care and other collaborators

Recruiting

Sisonke 2 - A COVID-19 Vaccine Boost Open Label Study. (Sisonke Boost)

SARS CoV 2 Infection

South Africa

Clinical Trials Sponsored by Janssen Infectious Diseases BVBA

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Papua New Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations